THURSDAY FEBRUARY 4

13:45 – 13:55 Opening Ceremony
EBMT President Prof. Nicolaus Kroeger & EHA President Prof. John Gribben

14:00 – 15:00 Session I, Clinical Indications 1
Chairs: Nicolaus Kroeger (DE) & John Gribben (UK)

- CAR T-cells for adult ALL Arnon Nagler (IL)
- Factors associated with outcomes of CD19 CAR T-cell therapy Cameron Turtle (US)
- Q&A

15:00 – 15:30 Break

15:30 – 16:30 Session II, Clinical Indications 2
Chairs: Claire Roddie (UK) & Chiara Bonini (IT)

- CAR T-cell therapy in large B-cell lymphomas: clinical indications Paolo Corradini (IT)
- CAR-T in Acute Myeloid Leukemia Gerhard Ehninger (DE)
- Mantle Cell Lymphoma Roch Houot (FR)
- Q&A

16:30 – 17:00 Break

17:00 – 17:45 Keynote Lecture
Chairs: Hermann Einsele (DE) & Christian Chabannon (FR)

- Strategies to improve efficacy of CAR T-cells in hematologic malignancies and solid tumors Stanley R. Riddell (US)
- Q&A

17:50 – 18:20 Best Abstracts and Flash Talks I

- Universal chimeric antigen receptor (CAR)-engineered T cells from induced pluripotent stem cells Alexandros Nianias (NL)
- Antibiotic-induced Microbiome Injury in CAR T-cell Patients correlates with Toxicity and Outcome Viktoria Blumenberg (DE)
- ARI-0001 CART19 cells in relapsed B-ALL with Isolated Extramedullary Disease Valentin Ortiz-Maldonado (SP)
- CD19 hypermethylation as an escape to CART-19 Michal Smida (CZ)

Chair: Maria Victoria Mateos (SP)

- Clinical advances with CAR-Ts and bispecifics in relapsed/refractory multiple myeloma Adam Cohen (US)
- A look into the future: possibilities for advanced therapy medicinal products in the management of patients with multiple myeloma Maria Victoria Mateos (SP)
- Pannel discussion and Q&A
FRIDAY FEBRUARY 5

09:00 – 09:45  Keynote Lecture
Chair: Marion Subklewe (DE) & Ibrahim Yakoub-Agha (FR)
- Progression of CAR T trials in China  Jianxiang Wang (CN)
- Q&A

09:45 – 10:00  Break

10:00 – 11:00  Session III - Optimizing CAR T-cell Therapy
Chair: Hermann Einsele (DE) & Arnon Nagler (IL)
- Mechanisms behind CAR T-cells  Marcela Maus (US)
- Virus-free CAR-T at the bench and in the clinic  Michael Hudecek (DE)
- Tumor glycosylation: impact on CAR T-cell efficacy  Monica Casucci (IT)
- Q&A

11:00 – 11:15  Break

11:15 – 12:15  Session IV - Pediatrics CAR T
Chair: Tobias Feuchtinger (DE) & Annette Künkele (DE)
- The challenges of CAR T-cell therapy for paediatric B-ALL  Sara Ghorashian (UK)
- Beyond CD19 CAR T cells for B-ALL  Rebecca Gardner (US)
- From hematological malignancies to solid tumor treatment: the journey of CAR T therapy in the pediatric setting  Concetta Quintarelli (IT)
- Q&A

12:20 – 12:50  Best Abstracts and Flash Talks II
- Proof-of-concept for Rapidly Switchable Universal CAR-T Platform with UniCAR-T-CD123 in Relapsed/Refractory AML  Martin Wermke (DE)
- CAR-Treg Therapy for Systemic Lupus Erythematos  Matteo Doglio (IT)
- JULIET: 40-month clinical update and biomarker analysis  Paolo Corradini (IT)
- Sleeping Beauty engineered CAR T cells for B-ALL  Chiara F. Magnani (IT)
- Characterisation and Clinical Outcomes of Different Bridging Strategies in patients receiving CD19CAR-T Therapy for Relapsed/Refractory B cell Lymphomas  Maria A. V. Marzolini (UK)
- CAR-HEMATOTOX: a multivariate score to predict hematotoxicity after CAR T-cell therapy for relapsed/refractory B-cell lymphoma  Kai Rejeski (DE)

13:00 – 13:45  Satellite Symposium by Kite and Gilead | Reaching new landmarks in survival with CAR T-cell therapy
Chair: Martin Dreyling (DE)
- CAR T-cell therapy in NHL: The story so far  (4-year landmark)  Anna Sureda (SP)
- Reshaping the treatment paradigm in R/R mantle cell lymphoma: Perspective on CAR T  Martin Dreyling (DE)
- Patient case discussion  Loïc Ysebaert (FR)
- Q&A

ALL SCHEDULES ARE BASED ON CENTRAL EUROPEAN TIME (CET)
13:45 – 15:00  Break

14:15 – 14:45 Meet the Expert Session: Marcela Maus (US)
No registration required. Limited space available

15:00 – 15:45 Satellite Symposium by Bristol Myers Squibb | Practical aspects of CAR T-cell therapy
Chair: Ulrich Jaeger (AT)

- CAR T-cell therapy in the daily care of patients with B-cell malignancies
  Peter Borchmann (DE)
- Implementation of CAR T-cell therapy in MM: practical and patient-related aspects
  Maria Victoria Mateos (SP)
- Q&A

15:50 – 16:50 Session V - Interactive pros / cons: future application of CAR T-cells
Chairs: Hermann Einsele (DE) & Fabio Ciceri (IT)

- BiTE vs CART: pro BiTE
  Marion Subklewe (DE)
- BiTE vs CART: pro CART
  Catherine Thieblemont (FR)
- CAR vs BiTEs in multiple myeloma
  Sebastien Anguille (BE)
- Q&A

16:55 – 17:55 Session VI - CAR effector cells (non T-cells)
Chairs: Claire Roddie (UK) & Michael Hudecek (DE)

- Adoptive cell therapy with tumor redirected
  iNKT cells
  Paolo Dellabona (IT)
- CARs NK
  Ulrike Koehl (DE)
- Allogeneic CAR Ts
  Reuben Benjamin (UK)
- Q&A

17:55 – 18:15  Break

18:15 – 19:00 Keynote Lecture
Chairs: Christian Chabannon (FR) & John Gribben (UK)

- Epigenetic landscaping of CAR T-cells - early insights
  Michel Sadelain (US)
- Q&A

19:05 – 19:50 IMI Project Workshop| How to rapidly move new CAR-Ts forward from bench to bedside? Key questions and answers!
Chairs: Michael Hudecek (DE) & Scott Wagers (BE)

Interactive panel discussion hosted by the imSAVAR and T2EVOLVE IMI projects
Michael Hudecek | Coordinator T2EVOLVE IMI Project
Ibtissam Marchiq, Project Leader Immuno-Oncology
Ulrike Koehl | Coordinator imSAVAR IMI Project
Jonathan Moggs | imSAVAR Industry Partner Coordinator
Stanley R. Riddell | Key Opinion Leader
FRIDAY FEBRUARY 5

10:00 – 10:05  Introduction and welcome
_Erik Aerts (CH)_

10:05 – 11:05  Session I
_Chair: Erik Aerts (CH)_
- Establishing a multiprofessional CAR T Cell Communication Board  Martina Spalt (AT)
- Immune Effector Cells in Solid Tumours  Jessica Ritchie (UK)
- Where are we now and where are we going with paediatric CART  Francesco Ceppi (CH)
- Q&A

11:05 – 11:15  Break

11:15 – 12:35  Session II
_Chair: John Murray (UK)_
- Post Infusion blood tests, what are they all for?  Amit Patel (UK)
- Does it work in other haematological diseases?  Reuben Benjamin (UK)
- What centre requirements are needed for JACIE  Rob Wosley (UK)
- GoCART  Sofie Terwel (NL)
- Q&A

12:35 – 15:45  Break

15:45 – 16:35  Session III
_Chair: Mairead Ni Chonghaile (IE)_
- Spotlight on the Lymphoma Patient Experience  Lorna Warwick (CA)
- Q&A
- Group Discussion – Ethics of CAR-T
  - Ruth Ting (UK)
  - Lorna Warwick (CA)
  - Erik Aerts (CH)
  - Martina Spalt (AT)

16:35 – 17:00  Break

17:00 – 18:00  Session IV
_Chair: Michelle Kenyon (UK)_
- Basic nursing care a training program  Ruth Clout (UK)
- Case study  Rose Ellard (UK)
- Survivorship Considerations After CAR T-Cell Therapy  Nicole Crisp (CA)
- Q&A

18:00 – 18:10  Closing remarks
_Michelle Kenyon (UK)_

Preliminary Programme
3rd European CAR T-cell Meeting
Virtual February 4 - 6, 2021

All schedules are based on Central European Time (CET)
SATURDAY FEBRUARY 6

**Physicians Programme**

**Session VII - side effects - recognition and treatment including novel insights into pathophysiology**
*Chairs: Monica Casucci (IT) & Marion Subklewe (DE)*

- Cytopenias post-CAR T-cell therapy  
  Ibrahim Yakoub-Agha (FR)
- CRS, ICANS and the steroids to prevent it  
  Max Topp (DE)
- Infections Complications of CAR T-cell Therapies: A Paradigm on the move  
  Joshua Hill (US)
- Q&A

**Session VIII: CAR T regulatory issue + reimbursements (in country and across borders)**
*Chairs: Michael Hudecek (DE) & Jurgen Kuball (NL)*

- Academic delivery through a national service  
  Alvaro Urbano-Ispizua (SP)
- CAR T Access: Importance of Reimbursement and Manufacturing Networks  
  Emanuele Ostuni (CH)
- Involving patients to solve the hurdles across the HTA process  
  Stephen Scowcroft (UK)
- Q&A

**Session IX: Data Management: real world data / LTFU / data collection**
*Chairs: Mohamad Mohty (FR) & Natacha Bolaños (SP)*

- Results of treatment with tisacel and axicel in real world conditions; report from the CIBMTR / CIDR  
  Marcelo Pasquini (US)
- Defining conditions for shared access to data collected in a global repository for EU CAR T-cells treated patients  
  Sofie Terwel (NL)
- CAR T-cells: the experience of patients and carers  
  Guy Bouguet (FR)
- Q&A

10:30 – 11:00  
Break
11:00 – 12:00  **Session X - Academic production**  
*Chairs: Stephan Mielke (SE) & Marion Subklewe (DE)*  
- Overcoming Cell Manufacturing Challenges in the Academic setting  
  Isabelle Riviere (US)  
- Why regulatory and commercial aspects should be improved for the successful ACT academic clinical trials  
  Manel Juan (SP)  
- Targeting SLAMF7 in Multiple Myeloma  
  Halvard Bönig (DE)  
- Q&A

11:00 – 12:00  **Session XI - Clinical challenges in CART**  
*Chairs: Claire Roddie (UK) & Max Topp (DE)*  
- Inclusion criteria  
  Catherine Thieblemont (FR)  
- Infectious complications in patients treated with CAR T-cells  
  Miguel Angel Perales (US)  
- Factors Associated with Outcomes of Repeat CD19-targeted CAR T-cell infusions for Refractory B cell Malignancies  
  Jordan Gauthier (US)  
- Q&A

11:00 – 12:00  **Session XII - EU grants and projects**  
*Chairs: Christine Chomienne (FR) & Michael Hudecek (DE)*  
- EN-ACTI²NG: from TCRs to CARs and back  
  Hisse M. van Santen (SP)  
  Ashwathi Menon (SP)  
  Tassilo Wachsmann (NL)  
  Lukas Velas (AT)  
- CARAMBA & EURE-CART H2020 projects  
  Michael Hudecek (DE)  
- imSAVAR & T2EVOLVE IMI projects  
  Ulrike Koehl (DE)  
  Partnering with patient organisations in H2020 projects such as CARAMBA  
- Q&A

12:00 – 12:30  **Break**

12:30 – 13:15  **Keynote Lecture**  
*Chairs: Ibrahim Yakoub-Agha (FR) & Hermann Einsele (DE)*  
- Updates with Engineered T Cells  
  Carl June (US)  
- Q&A

13:20 – 13:35  **Closing remarks**  
*Meeting Chairs: Christian Chabannon, Hermann Einsele*  
*EBMT President Prof. Nicolaus Kroeger & EHA President Prof. John Gribben*